Using a combination Pap and human papillomavirus test as the primary screening method for cervical cancer could result in improved detection rates compared with standard Pap tests, according to a study by U.K. researchers in the December 6 edition of The Lancet. Current screening approaches typically first employ a Pap test to detect signs of abnormal cervical cells, then a follow-up HPV test if abnormal cells are detected. HPV, a sexually transmitted virus, has been linked with almost all cervical cancer cases, and a negative HPV test as a follow-up to an abnormal Pap test typically rules out the risk of cancer. But the U.K. researchers, using Digene's combination Pap-HPV test on more than 10,300 women in five cities, found that the combination test was more sensitive than a standard Pap test alone, detecting 97.1% of precancerous cervical tissue, compared with 76.6% with the standard Pap test. "We have known for decades that HPV is the primary cause of cervix cancer," said lead researcher Jack Cuzick. "We now have a test that can very accurately detect its presence. Our findings are so promising that a pilot project should now be set up to see how the new test should be integrated into the existing cervical screening program."
Search
AI Powered
Human content,
AI powered search.
Latest Stories
Stay up to date with the latest in LGBTQ+ news with The Advocate’s email newsletter, in your inbox five days a week.
@ 2026 Equal Entertainment LLC.
All rights reserved
All rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
The Latest
Support Independent Journalism
LGBTQ+ stories deserve to betold.
Your membership powers The Advocate's original reporting—stories that inform, protect, and celebrate our community.
Become a Member
FOR AS LITTLE AS $5. CANCEL ANYTIME.
More For You
Most Popular
@ 2026 Equal Entertainment LLC. All Rights reserved













